Events

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 13th July, 2012
Time: Presentation 4:30pm, followed by drinks and nibbles
Venue: SBS Reception Lounge (Common Room)

Title: North to South, West to East – A Global Experience
Presented by Dr Suzanne Bertran, CE of NZBIO

Our guest speaker, Dr Suzanne Bertrand, has travelled south from the north end of the Northern Hemisphere and then half way round the world to live and work in New Zealand. On the way there was the US, China, Nth Africa....

Suzanne obtained her PhD in molecular biology at Laval University in Québec City and is now CE of NZBIO. In-between she has worked in both the public and private sector of the bio-industry as a research scientist, a consultant, a team manager and project leader, a start-up founder and CEO. In this presentation, Suzanne will focus on her experiences in establishing successful bio-industry operations in cultures vastly different to her own.

Suzanne was responsible for development projects in both Tunisia and China, where she lived in the Gansu province. Her projects involved many of the areas of bioscience around sustainability of food and the environment where NZ has much to offer globally, including soil analysis, water quality and plant physiology. Her experiences, though, translate even more broadly.

Suzanne experienced both frustration and great satisfaction as she learnt to operate in different cultures and different political systems and meet a range of expectations. Her ‘learning experiences’ were many. Suzanne learnt the importance of distinguishing between direct translation and developing a mutual understanding. She had the pleasure of overseeing the setting up of laboratories and systems entirely reliant on imported equipment evolving to those that were self-sufficient. She dealt with the obstacles to bringing western experts beyond the major cities to travel throughout the country to where they were needed. The list goes on..

Please join us to share Dr Suzanne Bertrand’s insights to the rewards and challenges faced by a westerner living and working in the bioscience sector in Nth Africa and China.

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email mailto:director@bioscienterprise.ac.nz or phone (09) 373 7599 ext 89625 or 0274 305 758.

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 18th May, 2012
Time: Presentation 4:30pm, followed by drinks and nibbles
Venue: SBS Reception Lounge (Common Room)

Title: Having The Stomach to Succeed
Presented by Dr Brian Ward, CEO of Wellington start-up Mesynthes

Having a promising technology – even a very promising technology – is one thing; going out on a limb (or an organ) to develop it is another. Choosing the best pathway to success is often a dilemma.

Dr Brian Ward, CEO of Wellington start-up Mesynthes, left the relative security of his role as the inaugural CEO of NZBIO just over 4 years ago in order to clean sheep stomachs. A lot has happened since then.

That cleaning is now a proprietary process that purifies and sterilizes the tissue to produce Endoform – an extracellular matrix containing structural proteins, adhesive proteins, glycosaminoglycans and growth factors. The resulting biomaterial is an exciting example of convergence of medical device and therapeutic technologies. Targeting the soft-tissue regeneration market (in excess of US$6 billion), it demonstrates quantitatively superior outcomes in vascularisation and rate and quality of repair. Mesynthes aims for Endoform to be the ECM platform of choice for regenerative medicine.

The lead product, Endoform Dermal Template or EDT, is used in chronic wound healing. With it, Mesynthes has completed very positive clinical trials, has achieved FDA 510k regulatory approval, has secured agreement with a multinational for distribution in Nth. America and agreement with another multinational in Europe for the development of a further wound care product.

Mesynthes has also established a certified cGMP facility with the capacity to meet the demand for commercial product of EDT for the next three years.

Two second generation products – Endoform Regenerative Template or ERT and Endoform Infection Control or EIC – are being developed. A 510k FDA application has been filed for ERT and EIC has achieved proof-of-concept.

With its products protected through patents, regulatory compliance and trade secrets as well as established partnerships with multinationals but also the potential to sell directly to niche markets, Mesynthes must decide on the best way forward from here.

Please join us as Dr Brian Ward’s discusses the development of a business strategy for taking a specialised NZ bioscience company to the global market.

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email director@bioscienterprise.ac.nz or phone (09) 923 9625 or 0274 305 758.

Public car parking is available nearby under the U of A’s Business School, the Owen G Glenn Building, in Grafton Rd. There is also limited parking available in Princes St.

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 27th April, 2012
Time: Presentation 4:30pm, followed by drinks and nibbles
Venue: SBS Reception Lounge (Common Room)

Title: Channelling Success
Presented by Brent Ogilvie, Pacific Channel’s founder and CEO.

As much as it sometimes seems that the bioindustry needs a little supernatural help, this is more of the guiding in the right direction type of channelling!

Pacific Channel
is now into its 7th year of providing support for young innovative life science companies. These companies range from bioactives and functional foods to biofuels; agbio and environmental technologies to diagnostics.

Pacific Channel has founded 7 companies with scientists to develop and commercialise novel technologies. Sourcing finance, providing guidance, management and governance as needed, Pacific Channel provides valuable survival tools to companies crossing the ‘valley of death’. They have placed investment of $0.5m to $5m for 14 ventures in 22 rounds totalling over NZD20m. This includes Pacific Channel’s role since mid-2008 as a seed and early stage investor in partnership with the NZ Venture Investment Fund, and a number of wealthy co-investors.

Pacific Channel’s founder and CEO, Brent Ogilvie, together with his colleagues Dr Robert Feldman and Mitali Purohit, will share their insight into what drives investment into start-up and early stage life science companies. Pacific Channel has led 20-33% of all seed & early stage NZ life science deals over the last 5 years and they will focus especially on what attracts both local and international capital to NZ companies.

Please join us as Pacific Channel shares its experience of the characteristics and attributes of companies that lead to investment and success.

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email director@bioscienterprise.ac.nz or phone (09) 373 7599 ext 89625 or 0274 305 758.

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 23th March, 2012
Time: Presentation 5pm, followed by drinks and nibbles
Venue: SBS Reception Lounge (Common Room)

Title: To List, or Not To List, That is the Question
Presented by David Blake, co-founder and co-editor of Bioshares.

Listing on the stock exchange is one of the key options for companies wanting financial security. But how to know when an IPO will be successful – and how to get to that point? Guest speaker David Blake, co-founder and co-editor of Bioshares will speak about the imperative for companies to have a well developed capital career plan from their inception if they are to maximise the probability of their success. Such an approach impacts on all aspects of the company; their business strategy, product development and management composition.

During his presentation, David will analyse the pathway to success for two listed Australian companies – Acrux (a drug delivery company that completed a $300M license deal) and Mesoblast (a $2B company based on adult stem cells).

Many of you will be familiar with Bioshares as Australia’s leading biotech stock report, delivering independent investment research to investors on ASX listed biotech, pharmaceutical and healthcare companies. It also organises a highly regarded Biotechnology summit each year designed to inform the investment sector and to encourage investment in the life science industry. Last year Bioshares had support from NZTE to hold this summit in New Zealand (Queenstown), attracting many international investors. The summit will be held in Queenstown again this year.

Please join us to discuss with David the mind set and practices he believes biocompanies need to adopt to maximise financial and investment success.

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email director@bioscienterprise.ac.nz or phone (09) 373 7599 ext 89625 or 0274 305 758.

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 24th February, 2012
Time: Presentation 4.30pm, followed by drinks and nibbles
Venue: SBS Reception Lounge (Common Room)

Title: Commercialisation Strategies for Innovating Firms
Presented by Associate Professor Simon Wakeman.

Associate Professor Simon Wakeman has been in New Zealand for the past two months applying his extensive knowledge of commercialisation in the US (by analysing over 1400 products) to issues for NZ companies. Simon describes his presentation as follows: A major issue for start-up firms is how to access the product development and marketing capabilities necessary to get an innovation to market. The decision whether and when to partner with an established firm not only influences the success of the innovation, but also how much value the innovator captures. However, there is considerable variation even within partnership arrangements. This seminar will outline the different arrangements used by biopharmaceutical firms to commercialize their innovation, focusing specifically on the choice between straight licensing arrangements and co-development arrangements. It will present data from the US biotech industry on what drives firms into one arrangement or the other, and how the choice affects their subsequent commercialization success.

Simon_Wakeman

Simon Wakeman is Associate Professor at the European School of Management and Technology (ESMT) in Berlin, Germany. He holds a PhD from the University of California at Berkeley, and prior to joining ESMT was a Research Fellow at the Center for Law & Biosciences at Stanford Law School. His research examines firm strategy for commercializing innovation, with a particular focus on the role that contractual arrangements and intellectual property rights play in that strategy. At ESMT he teaches courses on Business Strategy and Capturing Value from Innovation in the Full-Time MBA, Executive MBA, and Executive Education programs

You are warmly invited to join us to discuss Simon’s insights on how New Zealand companies can best capture value around innovation.

All welcome. RSVPs to Margot Bethell for organisational purposes would be greatly appreciated. Please email director@bioscienterprise.ac.nz or phone (09) 923 9625 or 0274 305 758.

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 9th December 2011
Time: Presentation – 4.30pm. Followed by drinks and nibbles
Venue: Reception Lounge, Main entrance of Thomas Building, 3 Symonds Street.
Speaker: Phil O’Reilly’s, Chief Executive of BusinessNZ
Title: Celebrating ‘Belgium’ (?!?....)

The last Bioscience Enterprise forum for 2011 is not to be missed. We will be celebrating.

We will be celebrating Phil O’Reilly’s vision of an economically vibrant New Zealand. From his position as Chief Executive of BusinessNZ, Phil’s stimulating presentation will look at what is needed to take the results of NZ's innovative skills into the global market.

We will be celebrating the 5th birthday of the MBioEnt qualification and the success of its ‘bilingual’ graduates in creating a bridge between the worlds of science and business.

We will be celebrating the successful completion of this year’s MBE theses as the 2011 interns now prepare to make their mark in the bioscience ecosystem.

We will be celebrating – and acknowledging – the wonderful support the programme has enjoyed from so many people across the bioindustry.

We will celebrate the end of the formalities with the eagerly anticipated, if somewhat inexpert, sabre champagne.

We would love you to join us to mark this occasion - and to debate how successfully the MBioEnt programme has contributed to Phil O’Reilly’s ‘Belgium’.

All welcome. RSVPs to Margot Bethell for organisational purposes would be greatly appreciated. Please email director@bioscienterprise.ac.nz or phone (09) 373 7599 ext. 89625 or 0274 305 758.


2011 Bioscience Enterprise Showcase

Tuesday 15th November; OGGB, University of Auckland

As many of you know, the University of Auckland’s Bioscience Enterprise programme is directed to people who want to see research realise its full value and impact on society by being successfully commercialised. A key element of this programme is the six month placement of interns with a bioscience company to work on a business-science project that forms the basis of their Master’s thesis. It is intended that these projects are of genuine value to the host company – many are currently hosting their 3rd, 4th, or even 5th intern.

We will be presenting the research undertaken by the 5th year of Bioscience Enterprise Master’s students and introducing you to the 2012 interns. This event is for all members of the bioscience industry who see value in the development of NZ’s bioeconomy with personnel who are ‘bilingual’ in both science and business.

The Showcase will allow you to:-

Hear about the science-business research projects that were important to biocompanies this year.

  • Meet the 2011 Master’s of Bioscience Enterprise graduates
  • Meet the 2012 Master’s of Bioscience Enterprise interns
  • Talk to other companies and organisations who are hosting, or have hosted, an MBioEnt intern and/or employed a MBioEnt graduate, as well as academic and programme supervisors
  • Explore the possibilities of the internship programme for your company
  • Be in at the beginning of the process of finding the best possible match between a company, the project and a 2012 internship student


You are warmly invited to attend all or part of the Showcase. Twelve minute presentations of the 2011 MBioEnt projects will run from 9.30 am to 3.00 pm and the Internship Fair will run from 3.00 to 5.00 pm. Posters of the research will be on display throughout the Showcase. The Showcase will be held in the University of Auckland’s Owen G Glenn Building/ Business School in Grafton Rd, Auckland.

You are also warmly invited to consider what science-business issues or projects could be of interest to your company or organisation in 2012 that could be researched by an MBioEnt student. I have attached a small sample of the more than 85 topics that have been investigated by these students over the past five years.

In a few weeks time I will send out further information. I will be inviting companies to nominate a project or projects, to register to meet prospective students before making a decision and/or to register to have a company stand.

In the meantime please feel very welcome to contact Margot Bethell with any queries.

Margot Bethell
Director Bioscience Enterprise Programme
Institute for Innovation in Biotechnology (IIB)
University of Auckland
email: director@bioscienterprise.ac.nz
phone: 373 7599 ext 89625mobile: +64 274 305 758

www.biotech.co.nz

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 14th October 2011
Time: Presentation – 4.30pm. Followed by drinks and nibbles
Venue: Reception Lounge, Main entrance of Thomas Building, 3 Symonds Street.
Speaker: Dr Fintan Walton, CEO and founder of PharmaVentures
Title: Pharma Ventured, Pharma Gains

Adapting to the huge changes taking place in pharma and biotech – including deals involving nutrition, orphan drugs, wound care, new technologies and even protection against bioterrorism –  PharmaVentures  continues to be a world leader in shaping deals and alliances in this sector.

We are delighted to welcome Dr Fintan Walton, CEO and founder of PharmaVentures, as the guest speaker at October’s forum.  PharmaVentures has 1000 clients in over 38 countries and has executed over 600 assignments for companies that include the major pharmas and biotechs from Baxter and Boehringer Ingleheim to J&J and Merck to Pfizer, Roche and Sanofi.

PharmaVentures assists corporations, investors and legal practices in all aspects of deal transactions, from strategy formulations to execution. It provides specialist strategic advice, transactional services and vital information to empower business decision makers. PharmaVentures also offers expert M&A and out-licensing services with staff experienced in both the life sciences and investment banking industries.

Fintan will examine the current global pharma environment and the impact this is having on the types of deals that are taking place.

Please join us to discuss with Fintan how the changing global trends in the pharma industry are of significance to New Zealand.

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email director@bioscienterprise.ac.nz  or phone (09) 373 7599 ext 89625 or 0274 305 758.



An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 16th September 2011
Time: Presentation – 4.30pm. Followed by drinks and nibbles
Venue: Reception Lounge, Main entrance of Thomas Building, 3 Symonds Street.
Speaker: David Fisher from Brandon Capital Partners (a Sydney based VC firm that have invested widely in the bioindustry)
Title: And it’s Aussie vs Kiwi....or maybe it’s more Aussie and Kiwi vs the Commercialisation Challenge.

Dr David Fisher, from the Sydney and Melbourne based firm Brandon Capital Partners, will be the guest speaker at the next Bioscience Enterprise forum. Brandon Capital Partners runs the Medical Research Commercialisation Fund, a very similar set up to the Trans Tasman Commercialisation Fund.

Like the TTCF, the MRCF has $30 million for ‘risk tolerant investment’ and, like the TTCF, is a mix of private and government funding. Both funds exclusively support research opportunities from their member organisations with up to $200,000 for research as early as proof-of-concept and a greater amount for supporting the formation of a company (up to $2 million with the MRCF).

The MRCF is a slightly more mature fund, starting in 2007. With the expectation of attracting approximately 10 members, the MRCF now has 27 member organisations.

David’s presentation will look at what has worked for the MRCF and what hasn’t; how they manage the assessment process; what makes a successful bid for funding; how they manage ‘co-opetition’ (where it is to all members’ advantage for the fund to succeed, also advantageous to collaborate to develop a commercial product, yet the funding is limited and, by definition, competitive); how they have worked with –and encouraged – co-investment.

The UofA has access to similar funding through the TTCF, but in co-opetition with four Australian Universities. Questions remain – would this funding model work for NZ Inc?; would NZ organisations support such a model?; is this model the best one for success for NZ companies?

Please join us to hear about David’s experience with the Medical Research Commercialisation Fund – and to contribute to the question. Do we want this for NZ too?

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email director@bioscienterprise.ac.nz or phone (09) 373 7599 ext 89625 or 0274 305 758.


An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 19th August 2011
Time: Presentation – 4.30pm. Followed by drinks and nibbles
Venue: Reception Lounge, Main entrance of Thomas Building, 3 Symonds Street.
Speaker: Sir Graeme Douglas – founder, owner and Director of Douglas Pharmaceuticals
Title: The Generic Guru

The Douglas Pharmaceutical story is one of adaptability, independence, adaptability, business strategy, and adaptability ... and loyal relationships...and excellent technical skills.

It is with great pleasure that we welcome Sir Graeme Douglas – founder, owner and Director of Douglas Pharmaceuticals – as the guest speaker for the next Bioscience Enterprise forum.

According to Sir Graeme, many people vastly underestimate what is involved in the production of generic medicines. He is referring to the necessary combination of planning, technical skill and financial resources. Add to that understanding Douglas Pharmaceuticals’ sought-after specialisation in the production of high containment, high potency and sometimes toxic drugs and you get some insight to this company’s success.

Set up in 1967 as an importer and distributer of pharmaceuticals, Douglas Pharmaceuticals now has an annual turnover of $150 million, derives 60% of its income from exports, employs 460 personnel – and is debt free. This impressive status is due in no small way to Sir Graeme’s response to challenge.

When NZ law restricted pharmacists to only one shop, Graeme set up his own import and distribution company. Introduction of huge tax penalties on imported goods? – Sir Graeme set up his own manufacturing plant (and an association with Sir Ray Avery for quality control). NZ law prevents even the development of drugs pre-patent expiry? - develop an R&D unit off-shore. Pharmac policy leads to huge loss of contracts? – expand the export market – a lot!

Please join us to gain further insight to this inspiring story direct from ‘the horse’s mouth’.

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email director@bioscienterprise.ac.nz or phone (09) 373 7599 ext 89625 or 0274 305 758.